Mouse methylome studies SRP388596 Track Settings
 
Decitabine-induced T cell remodeling facilitates a high antitumor response to PD-1 blockade therapy by promoting the expansion and effector function of CD8+ progenitor exhausted T cells [CD8+ T Cells]

Track collection: Mouse methylome studies

+  All tracks in this collection (559)

Maximum display mode:       Reset to defaults   
Select views (Help):
PMD       CpG methylation ▾       CpG reads ▾       AMR       HMR      
Select subtracks by views and experiment:
 All views PMD  CpG methylation  CpG reads  AMR  HMR 
experiment
SRX16716052 
SRX16716053 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX16716052  HMR  CD8+ T Cells / SRX16716052 (HMR)   Data format 
hide
 SRX16716052  AMR  CD8+ T Cells / SRX16716052 (AMR)   Data format 
hide
 SRX16716052  PMD  CD8+ T Cells / SRX16716052 (PMD)   Data format 
hide
 Configure
 SRX16716052  CpG methylation  CD8+ T Cells / SRX16716052 (CpG methylation)   Data format 
hide
 Configure
 SRX16716052  CpG reads  CD8+ T Cells / SRX16716052 (CpG reads)   Data format 
hide
 SRX16716053  HMR  CD8+ T Cells / SRX16716053 (HMR)   Data format 
hide
 SRX16716053  AMR  CD8+ T Cells / SRX16716053 (AMR)   Data format 
hide
 SRX16716053  PMD  CD8+ T Cells / SRX16716053 (PMD)   Data format 
hide
 Configure
 SRX16716053  CpG methylation  CD8+ T Cells / SRX16716053 (CpG methylation)   Data format 
hide
 Configure
 SRX16716053  CpG reads  CD8+ T Cells / SRX16716053 (CpG reads)   Data format 
    
Assembly: Mouse Jun. 2020 (GRCm39/mm39)

Study title: Decitabine-induced T cell remodeling facilitates a high antitumor response to PD-1 blockade therapy by promoting the expansion and effector function of CD8+ progenitor exhausted T cells
SRA: SRP388596
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX16716052 CD8+ T Cells 0.846 12.7 44213 1151.3 226 1106.7 3312 7374.4 0.992 GSM6411768: Con, WGBS; Mus musculus; Bisulfite-Seq
SRX16716053 CD8+ T Cells 0.843 13.7 47484 1111.2 329 1038.4 3236 7840.1 0.992 GSM6411769: DAC, WGBS; Mus musculus; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.